A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

Inclusion Criteria: * Histologic confirmation of primary malignancy. All primary tumor types may be enrolled. * Neoplastic meningitis/leptomeningeal metastasis refractory to conventional therapy with presence of tumor cells on cytology, OR neuroimaging evidence of leptomeningeal tumor by MRI. * Not eligible for higher priority clinical trial. * Have recovered from side effects of any surgical resection. * A stable dose of steroid for at least 7 days prior to the Gd-MRI. * Karnofsky Performance Status (KPS) of ≥ 60. * Laboratory Parameters: ANC ≥ 1.5 x 109/L; Hgb ≥ 9 g/dl; Platelets ≥ 100 x 109/L; AST and ALT ≤ 3.0 x ULN; Serum bilirubin ≤ 1.5 x ULN; Serum creatinine ≤ 1.5 x ULN; 24 hour creatinine clearance ≥ 50 ml/min * Life expectancy of at least 8 weeks. * Written informed consent obtained. Exclusion Criteria: * Concurrent therapy for leptomeningeal disease or other malignancy. * Clinical evidence of obstructive hydrocephalus or compartmentalization of CSF flow. * Cumulative doses: doxorubicin \> 450 - 550 mg/m2, epirubicin \> 800-1000 mg/m2, idarubicin \>130-150 mg/m2 and daunorubicin \> 400-550 mg/m2. * Anticonvulsant medications or other types of medications which are known to induce the CYP450 enzymes. * Pregnancy or breast feeding, or adults (male or female) of reproductive potential not employing an effective method of birth control * Total 24 hour urinary protein \> 500 mg. * Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study * Impaired cardiac function, other significant prior cardiac disease or arrhythmia of any type * Myocardial infarction ≤ 6 months prior * History of CHF or arrhythmias * Therapeutic doses of anticoagulant therapy (prophylactic dosing is allowed) * Investigational drugs less than 4 weeks prior; intrathecal chemotherapy within 2 weeks prior; systemic cytotoxic chemotherapy within 4 weeks prior (6 weeks for nitrosourea or mitomycin-C or 2 weeks for vincristine); radiation therapy within 2 weeks prior; any medication known to cause QT interval prolongation * Any surgery \<2 weeks prior